UK Sleep-Wake Disorder Market
UK Sleep-Wake Disorder Market Size, Share & Trends Analysis By Disorder Type (Insomnia, Hypersomnia, Sleep Apnea, Circadian Rhythm Sleep-Wake Disorders, Parasomnias, Dyssomnias, and Others), By Treatment Type (Pharmacological Therapy, Behavioral Therapy, Light Therapy, Device-Based Therapy, and Others), By Diagnosis & Management Approach (Polysomnography & Sleep Studies, Actigraphy-Based Monitoring, Clinical Evaluation & Screening Tools, and Remote/Digital Sleep Monitoring Solutions), and By Application (Hospitals, Home Care Settings, and Others), Forecast Period (2026-2035)
Industry Overview
UK sleep-wake disorder market was valued at $1.3 billion in 2025 and is projected to reach $2.3 billion by 2035, growing at a CAGR of 6.3% from 2026 to 2035. The growth of the UK sleep-wake disorder market is being supported by a combination of rising clinical awareness and improved recognition of sleep-related conditions across healthcare settings. The increasing prevalence of lifestyle-related sleep disturbances, driven by stress, irregular routines, and aging demographics, is contributing to higher diagnosis rates. Advances in diagnostic technologies and the wider availability of home-based sleep monitoring solutions are further strengthening patient identification. In parallel, expanding access to specialized treatments and therapeutic interventions is improving overall care pathways. The healthcare system’s growing emphasis on mental health and neurological well-being is also reinforcing demand for sleep disorder management solutions. Additionally, ongoing research and innovation in pharmacological and device-based therapies continue to support market expansion in the region.
Market Dynamics
Digital Sleep Monitoring and Home-Based Diagnostics
The UK sleep-wake disorder market is witnessing a notable shift toward digital sleep monitoring solutions and home-based diagnostic tools. Patients and healthcare providers are increasingly adopting wearable devices and connected platforms that enable continuous tracking of sleep patterns outside clinical settings. This trend is improving early detection rates and supporting more personalised treatment approaches. It is also reducing the dependency on hospital-based sleep studies, thereby improving accessibility and convenience. The integration of data analytics with sleep monitoring technologies is further enhancing clinical decision-making and long-term patient management outcomes.
Rising Adoption of Pharmacological and Non-Invasive Therapies
Another key trend shaping the UK market is the growing preference for both advanced pharmacological treatments and non-invasive therapeutic options for managing sleep-wake disorders. Pharmaceutical innovations targeting narcolepsy, insomnia, and related conditions are expanding the treatment landscape. At the same time, non-invasive approaches such as cognitive behavioural therapy for insomnia and neurostimulation-based solutions are gaining acceptance among clinicians and patients. This combined treatment evolution is improving adherence and long-term effectiveness of care. Increasing focus on safety, reduced side effects, and patient-centric care is further driving this balanced therapeutic adoption.
Market Segmentation
- Based on the disorder type, the market is segmented into insomnia, hypersomnia, sleep apnea, circadian rhythm sleep-wake disorders, parasomnias, dyssomnias, and others.
- Based on the treatment type, the market is segmented into pharmacological therapy, behavioral therapy, light therapy, device-based therapy, and others.
- Based on the diagnosis & management approach, the market is segmented into polysomnography & sleep studies, actigraphy-based monitoring, clinical evaluation & screening tools, and remote/digital sleep monitoring solutions.
- Based on the application, the market is segmented into hospitals, home care settings, and others.
Sleep Apnea Segment to Lead the Market with the Largest Share
The sleep apnea segment is experiencing steady expansion in the UK due to increasing detection rates and growing awareness of breathing-related sleep disturbances. Rising obesity levels and ageing population demographics are contributing significantly to the burden of the condition. Healthcare providers are placing greater emphasis on early screening and long-term management, which is improving diagnosis volumes. Key companies such as ResMed Inc., Koninklijke Philips N.V., and Fisher & Paykel Healthcare Corporation Limited continue to influence the market through advanced respiratory support solutions. Recent developments show a stronger shift toward compact, home-use therapeutic devices with digital monitoring capabilities. Integration of connected health systems is further enhancing treatment adherence and patient outcomes in this segment.
Pharmacological Therapy: A Key Segment in Market Growth
The pharmacological therapy segment is gaining traction in the UK sleep-wake disorder market owing to the increasing incidence of insomnia, narcolepsy, and related neurological conditions. Growing clinical preference for targeted drug-based interventions is supporting segment expansion. Pharmaceutical innovation is focusing on improved efficacy profiles with reduced dependency risks and better patient tolerance. Companies such as Jazz Pharmaceuticals plc, Takeda Pharmaceutical Company Limited, and Eli Lilly and Company are actively contributing to advancements in this area. Recent trends indicate stronger regulatory support for specialty sleep medications and orphan indications. Expanding access to specialist sleep disorder treatments through hospital and retail channels is further strengthening demand in this segment.
Market Players Outlook
The major companies operating in the UK sleep-wake disorder market include GlaxoSmithKline plc, AstraZeneca plc, Eli Lilly and Company, Jazz Pharmaceuticals plc, and Pfizer Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Development
- In 2025, UK-based healthtech firm 32Co initiated the rollout of Aerox Sleep Centers to improve access to diagnosis and treatment for obstructive sleep apnoea and snoring disorders. The model focuses on decentralizing care through a network of localized sleep clinics, including pilot centers across London, Manchester, Edinburgh, and Bristol.
The Report Covers
- Market value data analysis for 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Key companies operating in the UK sleep-wake disorder market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- UK Sleep-Wake Disorder Market Sales Analysis – Disorder Type | Treatment Type | Diagnosis & Management Approach | Application ($ Million)
- Sleep-Wake Disorder Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Sleep-Wake Disorder Industry Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Sleep-Wake Disorder Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For UK Sleep-Wake Disorder Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For UK Sleep-Wake Disorder Market: Impact Analysis
- Market Opportunities
- Opportunities For UK Sleep-Wake Disorder Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Sleep-Wake Disorder Market Revenue and Share by Manufacturers
- Sleep-Wake Disorder Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- AstraZeneca plc
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Eli Lilly and Company
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- GlaxoSmithKline plc
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Jazz Pharmaceuticals plc
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Pfizer Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership and Collaboration
- AstraZeneca plc
- Key Company Analysis
- UK Sleep-Wake Disorder Market Sales Analysis by Disorder Type ($ Million)
- Insomnia
- Hypersomnia
- Sleep Apnea
- Circadian Rhythm Sleep-Wake Disorders
- Parasomnias
- Dyssomnias
- Others
- UK Sleep-Wake Disorder Market Sales Analysis by Treatment Type ($ Million)
- Pharmacological Therapy
- Behavioral Therapy
- Light Therapy
- Device-Based Therapy
- Others
- UK Sleep-Wake Disorder Market Sales Analysis by Diagnosis & Management Approach ($ Million)
- Polysomnography & Sleep Studies
- Actigraphy-Based Monitoring
- Clinical Evaluation & Screening Tools
- Remote / Digital Sleep Monitoring Solutions
- UK Sleep-Wake Disorder Market Sales Analysis by Application ($ Million)
- Hospitals
- Home Care Settings
- Others
- Company Profiles
- Acorda Therapeutics, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AstraZeneca plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Becton, Dickinson and Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Compumedics Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Reddy’s Laboratories Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eisai Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eli Lilly and Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Fisher & Paykel Healthcare Corp. Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GlaxoSmithKline plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Harmony Biosciences Holdings, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Jazz Pharmaceuticals plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Koninklijke Philips N.V.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Medtronic plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck & Co., Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Natus Medical Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Neurocrine Biosciences, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Otsuka Holdings Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- ResMed Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- SomnoMed Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Takeda Pharmaceutical Company Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Teva Pharmaceutical Industries Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Vanda Pharmaceuticals Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Viatris Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Acorda Therapeutics, Inc.
1. UK Sleep-Wake Disorder Market Research and Analysis by Disorder Type, 2025-2035 ($ Million)
2. UK Insomnia Disorder Market Research and Analysis, 2025-2035 ($ Million)
3. UK Hypersomnia Disorder Market Research and Analysis, 2025-2035 ($ Million)
4. UK Sleep Apnea Disorder Market Research and Analysis, 2025-2035 ($ Million)
5. UK Circadian Rhythm Sleep-Wake Disorder Market Research and Analysis, 2025-2035 ($ Million)
6. UK Parasomnias Disorder Market Research and Analysis, 2025-2035 ($ Million)
7. UK Dyssomnias Disorder Market Research and Analysis, 2025-2035 ($ Million)
8. UK Other Sleep-Wake Disorder Market Research and Analysis, 2025-2035 ($ Million)
9. UK Sleep-Wake Disorder Market Research and Analysis by Treatment Type, 2025-2035 ($ Million)
10. UK Sleep-Wake Disorder by Pharmacological Therapy Market Research and Analysis, 2025-2035 ($ Million)
11. UK Sleep-Wake Disorder by Behavioral Therapy Market Research and Analysis, 2025-2035 ($ Million)
12. UK Sleep-Wake Disorder by Light Therapy Market Research and Analysis, 2025-2035 ($ Million)
13. UK Sleep-Wake Disorder by Device-Based Therapy Market Research and Analysis, 2025-2035 ($ Million)
14. UK Sleep-Wake Disorder by Other Treatment Type Market Research and Analysis, 2025-2035 ($ Million)
15. UK Sleep-Wake Disorder Market Research and Analysis by Diagnosis & Management Approach, 2025-2035 ($ Million)
16. UK Polysomnography & Sleep Studies Market Research and Analysis, 2025-2035 ($ Million)
17. UK Actigraphy-Based Monitoring Market Research and Analysis, 2025-2035 ($ Million)
18. UK Clinical Evaluation & Screening Tools Market Research and Analysis, 2025-2035 ($ Million)
19. UK Remote / Digital Sleep Monitoring Solutions Market Research and Analysis, 2025-2035 ($ Million)
20. UK Sleep-Wake Disorder Market Research and Analysis by Application, 2025-2035 ($ Million)
21. UK Sleep-Wake Disorder for Hospitals Market Research and Analysis, 2025-2035 ($ Million)
22. UK Sleep-Wake Disorder for Home Care Settings Market Research and Analysis, 2025-2035 ($ Million)
23. UK Sleep-Wake Disorder for Other Application Market Research and Analysis, 2025-2035 ($ Million)
1. UK Sleep-Wake Disorder Market Share by Disorder Type, 2025 Vs 2035 (%)
2. UK Insomnia Disorder Market Share, 2025 Vs 2035 (%)
3. UK Hypersomnia Disorder Market Share, 2025 Vs 2035 (%)
4. UK Sleep Apnea Disorder Market Share, 2025 Vs 2035 (%)
5. UK Circadian Rhythm Sleep-Wake Disorder Market Share, 2025 Vs 2035 (%)
6. UK Parasomnias Disorder Market Share, 2025 Vs 2035 (%)
7. UK Dyssomnias Disorder Market Share, 2025 Vs 2035 (%)
8. UK Other Sleep-Wake Disorder Market Share, 2025 Vs 2035 (%)
9. UK Sleep-Wake Disorder Market Share by Treatment Type, 2025 Vs 2035 (%)
10. UK Sleep-Wake Disorder by Pharmacological Therapy Market Share, 2025 Vs 2035 (%)
11. UK Sleep-Wake Disorder by Behavioral Therapy Market Share, 2025 Vs 2035 (%)
12. UK Sleep-Wake Disorder by Light Therapy Market Share, 2025 Vs 2035 (%)
13. UK Sleep-Wake Disorder by Device-Based Therapy Market Share, 2025 Vs 2035 (%)
14. UK Sleep-Wake Disorder by Other Treatment Type Market Share, 2025 Vs 2035 (%)
15. UK Sleep-Wake Disorder Market Share by Diagnosis & Management Approach, 2025 Vs 2035 (%)
16. UK Polysomnography & Sleep Studies Market Share, 2025 Vs 2035 (%)
17. UK Actigraphy-Based Monitoring Market Share, 2025 Vs 2035 (%)
18. UK Clinical Evaluation & Screening Tools Market Share, 2025 Vs 2035 (%)
19. UK Remote / Digital Sleep Monitoring Solutions Market Share, 2025 Vs 2035 (%)
20. UK Sleep-Wake Disorder Market Share by Application, 2025 Vs 2035 (%)
21. UK Sleep-Wake Disorder for Hospitals Market Share, 2025 Vs 2035 (%)
22. UK Sleep-Wake Disorder for Home Care Settings Market Share, 2025 Vs 2035 (%)
23. UK Sleep-Wake Disorder for Other Application Market Share, 2025 Vs 2035 (%)
- Printable version
- No restriction to number of users within the company
